Cargando…
Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies
BACKGROUND: Patient selection for transarterial chemoembolization (TACE) has remained challenging. Currently used markers mainly reflect liver function and turned out as less reliable in larger clinical trials. The patients´ body composition has been linked with patient outcome in different cancers....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356883/ https://www.ncbi.nlm.nih.gov/pubmed/36689060 http://dx.doi.org/10.1007/s00432-022-04519-8 |
_version_ | 1785075374257864704 |
---|---|
author | Loosen, Sven H. Jördens, Markus S. Schoon, Berenike Antoch, Gerald Luedde, Tom Minko, Peter Loberg, Christina Roderburg, Christoph |
author_facet | Loosen, Sven H. Jördens, Markus S. Schoon, Berenike Antoch, Gerald Luedde, Tom Minko, Peter Loberg, Christina Roderburg, Christoph |
author_sort | Loosen, Sven H. |
collection | PubMed |
description | BACKGROUND: Patient selection for transarterial chemoembolization (TACE) has remained challenging. Currently used markers mainly reflect liver function and turned out as less reliable in larger clinical trials. The patients´ body composition has been linked with patient outcome in different cancers. Now, we analyzed the function of different parameters of the patient’s body composition as prognostic and/ or predictive parameters in patients that received TACE. METHODS: CT scans were used to assess five parameters of the individual body composition (skeletal muscle index (SMI), median muscular attenuation (MMA), bone mineral density (BMD) as well as the visceral and subcutaneous fat area) in 89 patients undergoing TACE. Results were correlated with tumor response to TACE and outcome of patients. RESULTS: SMI and visceral fat area were significantly higher in male patients and among patients undergoing TACE for HCC compared to patients with liver metastases. While all parameters of the body composition did not predict response to TACE, patients with an SMI below the ideal cutoff value of 37.76 cm(2)/m(2) had a significantly reduced long-term outcome with a median overall survival of 404 days compared to 1321 days for patients with a high SMI. Moreover, the pre-interventional SMI turned out as an independent prognostic factor in a multivariate Cox regression model including clinicopathological parameters and laboratory markers of organ dysfunction and systemic inflammation (HR: 0.899, 95% CI 0.827–0.979, p = 0.014). CONCLUSION: The pre-interventional SMI represents an independent prognostic factor for overall survival following TACE. Assessment of the individual body composition using routine CT scan might help to identify the ideal patients for TACE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-022-04519-8. |
format | Online Article Text |
id | pubmed-10356883 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-103568832023-07-21 Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies Loosen, Sven H. Jördens, Markus S. Schoon, Berenike Antoch, Gerald Luedde, Tom Minko, Peter Loberg, Christina Roderburg, Christoph J Cancer Res Clin Oncol Research BACKGROUND: Patient selection for transarterial chemoembolization (TACE) has remained challenging. Currently used markers mainly reflect liver function and turned out as less reliable in larger clinical trials. The patients´ body composition has been linked with patient outcome in different cancers. Now, we analyzed the function of different parameters of the patient’s body composition as prognostic and/ or predictive parameters in patients that received TACE. METHODS: CT scans were used to assess five parameters of the individual body composition (skeletal muscle index (SMI), median muscular attenuation (MMA), bone mineral density (BMD) as well as the visceral and subcutaneous fat area) in 89 patients undergoing TACE. Results were correlated with tumor response to TACE and outcome of patients. RESULTS: SMI and visceral fat area were significantly higher in male patients and among patients undergoing TACE for HCC compared to patients with liver metastases. While all parameters of the body composition did not predict response to TACE, patients with an SMI below the ideal cutoff value of 37.76 cm(2)/m(2) had a significantly reduced long-term outcome with a median overall survival of 404 days compared to 1321 days for patients with a high SMI. Moreover, the pre-interventional SMI turned out as an independent prognostic factor in a multivariate Cox regression model including clinicopathological parameters and laboratory markers of organ dysfunction and systemic inflammation (HR: 0.899, 95% CI 0.827–0.979, p = 0.014). CONCLUSION: The pre-interventional SMI represents an independent prognostic factor for overall survival following TACE. Assessment of the individual body composition using routine CT scan might help to identify the ideal patients for TACE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-022-04519-8. Springer Berlin Heidelberg 2023-01-23 2023 /pmc/articles/PMC10356883/ /pubmed/36689060 http://dx.doi.org/10.1007/s00432-022-04519-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Loosen, Sven H. Jördens, Markus S. Schoon, Berenike Antoch, Gerald Luedde, Tom Minko, Peter Loberg, Christina Roderburg, Christoph Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies |
title | Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies |
title_full | Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies |
title_fullStr | Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies |
title_full_unstemmed | Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies |
title_short | Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies |
title_sort | sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (tace) for hepatic malignancies |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356883/ https://www.ncbi.nlm.nih.gov/pubmed/36689060 http://dx.doi.org/10.1007/s00432-022-04519-8 |
work_keys_str_mv | AT loosensvenh sarcopeniaindicatepoorsurvivalinpatientsundergoingtransarterialchemoembolizationtaceforhepaticmalignancies AT jordensmarkuss sarcopeniaindicatepoorsurvivalinpatientsundergoingtransarterialchemoembolizationtaceforhepaticmalignancies AT schoonberenike sarcopeniaindicatepoorsurvivalinpatientsundergoingtransarterialchemoembolizationtaceforhepaticmalignancies AT antochgerald sarcopeniaindicatepoorsurvivalinpatientsundergoingtransarterialchemoembolizationtaceforhepaticmalignancies AT lueddetom sarcopeniaindicatepoorsurvivalinpatientsundergoingtransarterialchemoembolizationtaceforhepaticmalignancies AT minkopeter sarcopeniaindicatepoorsurvivalinpatientsundergoingtransarterialchemoembolizationtaceforhepaticmalignancies AT lobergchristina sarcopeniaindicatepoorsurvivalinpatientsundergoingtransarterialchemoembolizationtaceforhepaticmalignancies AT roderburgchristoph sarcopeniaindicatepoorsurvivalinpatientsundergoingtransarterialchemoembolizationtaceforhepaticmalignancies |